Compare Eli Lilly And Co (LLY) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Snap Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Snap Inc trades at $6.24 (market cap $9.83B). The key difference: Eli Lilly And Co is far larger — about 105.8× Snap Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Snap Inc for 68 Days on average.
| LLY | SNAP | |
|---|---|---|
Market Cap | $1.04T | $9.83B |
Volume | 3,064,878 | 28,532,342 |
Sector | Health | Media |
52-Week High | $1.28K | $9.09 |
52-Week Low | $799.57 | $3.93 |
Typical Hold Time | 93 Days | 68 Days |
Enterprise Value | $1.09T | $11.39B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Snap stock trades at $5.865, up 0.95% on the day, with a bullish technical signal from moving averages. Revenue grew to $5.93 billion in 2025, and net losses narrowed to -$460 million, showing improving profitability. Recent news highlights the launch of SPECS Intelligence AI and enterprise partnerships with NVIDIA and Salesforce, driving positive sentiment. The consensus price target is $7.78, with 38% of analysts rating it a Buy.
The outlook remains cautious but improving, as revenue growth and narrowing losses present opportunity, but persistent net losses and high debt pose risks. Regulatory pressures and intense social media competition are key challenges. Analyst consensus leans Hold, reflecting a wait-and-see approach amid ongoing transformation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
